Orthogon Therapeutics, a developer of novel antiviral medicines, has announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing total funding to over $25M. This funding will accelerate the development of its first-in-class treatments for managing BK virus reactivation in transplant patients.

Orthogon leverages advanced structure-based drug design and biophysics to create groundbreaking therapies for challenging drug targets.